Endocyte Inc. buy stratec
Start price
18.10.18
/
50%
€21.06
Target price
18.10.18
€21.65
Performance (%)
0.39%
End price
18.10.18
€21.14
Summary
This prediction ended on 18.10.18 with a price of €21.14. The BUY prediction by stratec for Endocyte Inc. closed nearly unchanged. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Endocyte Inc. | - | - | - | - |
| iShares Core DAX® | 0.597% | 3.083% | 16.090% | 16.439% |
| iShares Nasdaq 100 | 0.899% | 5.338% | 29.239% | 56.431% |
| iShares Nikkei 225® | 1.775% | -1.206% | 6.823% | 4.774% |
| iShares S&P 500 | 0.990% | 3.500% | 24.956% | 47.182% |
Comments by stratec for this prediction
In the thread Endocyte Inc. diskutieren
Endocyte is working on developing therapy to combat tumors
The company is also focused on developing promising companion agents for identifying patients most likely to benefit from its targeted therapy.
Endocyte is preparing to enter its adaptor-controlled CAR-T program in clinic in Q4 2018.
Lutetium-PSMA-617 is a promising radioligand therapy targeting advanced prostate cancer.